AstraZeneca’s Anders Persson new Chairman of the Board of SwedenBIO

New chairman and two new board members to the SwedenBIO board.

Anders Persson has been an ordinary board member of SwedenBIO since 2021 and was elected to the position of chairman during the annual general meeting held in Stockholm on May 14. He succeeds Lotta Ljungqvist who has held the role since 2021.

– It feels extremely exciting and stimulating to take on the role as chairman of SwedenBIO. I am really looking forward to working with SwedenBIO’s board and CEO Jessica Martinsson to develop the impressive network that the organization has built up over the years. My focus will be on giving SwedenBIO an even stronger voice in life science issues, creating as much benefit as possible for the member companies, and together with them contribute to strengthening the Swedish life science sector, says Anders Persson.

Anders Persson leads the ecosystem strategy for AstraZeneca R&D in Gothenburg. He has over 25 years of experience in global drug development across all phases of the value chain and through both drug project responsibilities, senior leadership roles as well as leading major organizational change. A common thread in Anders’ career has been to constantly challenge the status quo and to seek opportunities for business improvement, always with a focus on the big picture. Anders has studied biology, chemistry and has a PhD in Biochemistry at Lund University.

– I look forward to working closely with Anders and I am convinced that his unique position in our community, with insights from both the global pharmaceutical company and the dynamic startup environment will add extra value to all our members, comments Jessica Martinsson, CEO & Director General at SwedenBIO.

Renée Aguiar-Lucander, CEO, Calliditas and Sara Corin, General Manager for Downstream Hardware and Consumables, Cytiva, were elected as new Board members. Kerstin Falck, Director Policy & Public Affairs Lead, Pfizer, takes over the role of Vice Chair.

SwedenBIO was founded over 20 years ago and has grown to become Sweden’s and the Nordic region’s largest life science industry organization with over three hundred member companies. At the same time, the importance of the sector to the Swedish economy has increased with rising pharmaceutical exports, more companies and new jobs. The question of how Sweden can maintain and strengthen its position as a leading life science nation is moving higher up the political agenda and SwedenBIO’s role as an important voice for the industry is becoming increasingly central.

The new Board in its entirety:
Chairman: Anders Persson, AstraZeneca
Vice Chair: Kerstin Falck, Pfizer
Members of the Board of Directors:
Sana Alajmovic, Sigrid Therapeutics
Carl Kilander, HealthCap
Christin Wesström, Sobi
Mårten Winge, Strike Pharma
Renee Lucander, Calliditas
Sara Corin, Cytiva